antidiabetic drugs

Albiglutide - Alogliptin - Canagliflozin - Dapagliflozin - Empagliflozin - Exenatide - Glipizide - Glyburide - Liraglutide - Lixisenatide - Metformin - Nateglinide - Pioglitazone - Rosiglitazone - Saxagliptin - Sitagliptin - Sulfonylurea - Taspoglutide - Troglitazone - Voglibose      

Select            
Trial Studied trt Control trt patientstagsROB Trial resultAll cause deathcardiovascular events

diabetes type 2

albiglutide
Rosenstock (30 mg weekly), 2009      NCTalbiglutide weeklyplacebo (add on MET)Exploratory suggesting
alogliptin
Nauck, 2009      NCTalogliptinplacebo (add on MET)Low risk of bias negative
dapagliflozin
Bailey (MB102014), 2010          NCTdapagliflozinplacebo (add on MET)Low risk of bias -
exenatide
Buse, 2011      NCTexenatide 20µg/dplacebo (add on insulin)Low risk of bias negative -100%
Fineman, 2003     exenatide other dosesplacebo (add on MER+/-SU)Exploratory -
DeFronzo 10µg/d, 2005          NCTexenatide 10µg/dplacebo (add on MET)Low risk of bias negative
DeFronzo 20µg/d, 2005      NCTexenatide 20µg/dplacebo (add on MET)Low risk of bias suggesting
Kim, 2007      NCTexenatide weeklyplacebo (add on MET)Exploratory negative
Gao, 2009      NCTexenatide 20µg/dplacebo (add on MET+/-SU)Low risk of bias suggesting -100%
Buse 10µg/d, 2004          NCTexenatide 10µg/dplacebo (add on SU)negative
Buse 20µg/d, 2004     exenatide 20µg/dplacebo (add on SU) -
Kadowaki (trial 8683), 2009     exenatide 10µg/dplacebo (add on SU+/-MET/TZD)Exploratory negative
Kendall 10µg/d, 2005      NCTexenatide 10µg/dplacebo (add on SU+MET)Low risk of bias negative
Kendall 20µg/d, 2005      NCTexenatide 20µg/dplacebo (add on SU+MET)Low risk of bias suggesting -100%
Zinman 20µg/j, 2007    NCTexenatide 20µg/dplacebo (add on TZD+/-MET)Low risk of bias suggesting
Zinman 20µg/j A MODIFIER, 2007   exenatide 20µg/dplacebo (add on TZD+/-MET)Low risk of bias -
phase 2 exenatide once monthly   exenatide once monthlyweekly exenatide -
Exenatide Trial 10749   exenatide before lunch and dinnerexenatide before breakfast and dinnerRisk of bias -
Heine, 2005   exenatide 20µg/dinsulin (add on SU+MET)negative 58%
Davis, 2007      NCTexenatide 20µg/dinsulin (add on SU/MET)Risk of bias negative +Infini%
Barnett, 2007      NCTexenatide 20µg/dinsulin (add on SU/MET)Exploratory suggesting
Nauck, 2007      NCTexenatide 20µg/dinsulin BIAsp twice daily add on SU+METRisk of bias negative 96%96%
DURATION-3 (Diamant), 2010    NCTexenatide weeklyinsulin glargineRisk of bias suggesting +Infini%
Trial 8078   exenatide other dosesinsulin glargine (add on MET/SU) -
glimeripide
Study 201 (Goldberg), 1996   glimepirideplaceboLow risk of bias -
Schade, 1998   glimepirideplaceboLow risk of bias -
Rosenstock, 1996   glimepirideplaceboLow risk of bias -
Luis Bautista, 2003   glimepirideplaceboLow risk of bias -
Kaneko, 1993   glimepirideplacebo -
Study 202   glimepirideplacebo -
Riddle, 1994   glimepirideplacebo (add on insulin) -
Charpentier, 2001     glimepirideplacebo (add on MET)Low risk of bias negative
Draeger, 1996     glimepirideglibenclamideLow risk of bias -
Protocol 311   glimepirideglibenclamide -
Charpentier (301F)   glimepiridegliclazide -
Inukai, 2005     glimepiridegliclazide or glibenclamide -
Sonnenberg, 1997   glimepiride odglimepiride bid -
Clark (301), 1997   glimepirideglipizide -
Dills, 1996   glimepirideglyburideLow risk of bias -
glipizide
Goldstein   glipizidecontrol (add on MET) -
Rosenstock, 1993   glipizideglyburide -
Birkeland, 1994   glipizideglyburide -
Birkeland, 1994   glipizideglyburideLow risk of bias -
Simonson, 1997   glipizideplaceboLow risk of bias -
Testa, 1998   glipizideplacebo -
glyburide
Hermann, 1991   glibenclamidec (add on MET) -
DeFronzo, 1995   glyburidec (add on MET)Low risk of bias -
Erle, 1999   glyburidec (add on MET) -
Marre (ass), 2002   glibenclamidecontrol (add on MET)Low risk of bias -
Tosi, 2003   glibenclamidecontrol (add on MET)Low risk of bias -
Blonde, 2002   glyburidecontrol (add on MET)Low risk of bias -
Garber, 2003   glyburidecontrol (add on MET) -
Garber, 2002   glyburideplaceboLow risk of bias -
Vray, 1995   glyburideplaceboLow risk of bias -
linagliptin
Gallwitz, 2012      NCTlinagliptinglimepiride (add on MET)Low risk of bias -
Owens      NCTlinagliptinMetformin + sulfonylurea -
Del Prato      NCTlinagliptinplaceboLow risk of bias -
Lewin, 2010    NCTlinagliptinplacebo (add on SU)Low risk of bias -
liraglutide
LEAD-2 (Nauck) (1.8mg vs placebo), 2009      NCTliraglutide 1.8mgplacebo (add on MET)Low risk of bias suggesting
LEAD-1 SU (1.2 mg vs placebo), 2009        NCTliraglutide 1.2mgplacebo (add on SU)Low risk of bias suggesting
LEAD-1 SU (1.8 mg vs placebo), 2009      NCTliraglutide 1.8mgplacebo (add on SU)Low risk of bias suggesting
LEAD-5 (vs placebo), 2009      NCTliraglutide 1.8mgplacebo (add on SU+MET)Low risk of bias suggesting 148%
LEAD-4 (1.2mg), 2009      NCTliraglutide 1.2mgplacebo (add on TZD+MET)Low risk of bias suggesting24%
LEAD-4 (1.8mg), 2009      NCTliraglutide 1.8mgplacebo (add on TZD+MET)Low risk of bias suggesting-25%
LEAD-6, 2009        NCTliraglutide 1.8mgexenatide on top MET/SU/MET+SURisk of bias suggesting
Seino, 2010      NCTliraglutide other dosesglibenclamideLow risk of bias negative+Infini%
LEAD-2 (Nauck) (1.8 mg vs glimepiride), 2009      NCTliraglutide 1.8mgglimepiride (add on MET)Low risk of bias negative
LEAD-5 (vs Glargine), 2009    NCTliraglutide 1.8mginsulin glargine (add on SU+MET)Risk of bias negative
LEAD-1 SU (1.8 vs rosiglitazone), 2009      NCTliraglutide other dosesrosiglitazone (add on SU)Low risk of bias suggesting
Pratley 1.2mg, 2010      NCTliraglutide 1.2mgsitagliptinRisk of bias suggesting -100%-3%
Pratley 1.8mg, 2010    NCTliraglutide 1.8mgsitagliptinLow risk of bias suggesting 0%-3%
lixisenatide
GETGOAL-L    NCTlixisenatideplacebo (add on basal insulin)Low risk of bias -
Ratner DRI6012, 2010      NCTlixisenatideplacebo (add on MET)Exploratory -
mitiglinide
Gao      NCTmitiglinidenateglinideLow risk of bias -
Kumashiro, 2007     mitiglinideon top insulin glargine -
Kaku, 2009     mitiglinideplacebo (on top pioglitazone) -
nateglinide
Marre, 2002     nateglinideplaceboLow risk of bias -
Horton, 2000   nateglinideplaceboLow risk of bias -
Hanefeld, 1990   nateglinideplaceboLow risk of bias -
Saloranta, 2002   nateglinideplaceboLow risk of bias -
Mari, 2005   nateglinideplacebo -
Moses, 2001   nateglinideplaceboLow risk of bias -
Goldberg, 1998   repaglinideplaceboLow risk of bias -
Jovanovic, 2000   repaglinideplaceboLow risk of bias -
Bech, 2003   repaglinideplaceboLow risk of bias -
Li, 2009   nategliniderepaglinide -
Li, 2007   nategliniderepaglinide -
Ristic, 2006       nateglinidegliclazide (add on MET)Low risk of bias -
pioglitazone
PNFP-014   pioglitazone + insulinplacebo (add on insulin)Exploratory negative
OPI-502   pioglitazone + insulinplacebo (add on insulin)Exploratory negative
repaglinide
Moses, 1999     repaglinidecontrol (add on MET)Exploratory -
Landgraf, 1999   repaglinideglibenclamideLow risk of bias -
Marbury, 1999   repaglinideglibenclamide -
Wolffenbuttel, 1999   repaglinideglibenclamideLow risk of bias -
Madsbad, 2001   repaglinideglipizideLow risk of bias -
Lund, 2007   repaglinidemetforminLow risk of bias -
Raskin, 2001   repaglinideon top pioglitazone -
Raskin, 2001   repaglinideon top rosiglitazone -
Raskin, 2000   repaglinideon top troglitazone -
Chuang, 1999   repaglinideplacebo -
Goldberg, 1998   repaglinideplaceboExploratory -
Jovanovic, 2000   repaglinideplaceboLow risk of bias -
Landin-Olsson, 1999   repaglinideplacebo (on top bedtime NPH-insulin) -
rosiglitazone
SB-712753/009   rosiglitazoneExploratory -
49653/136   rosiglitazoneplaceboExploratory -
BRL 49653/347    NCTrosiglitazoneplacebo (add on insulin)Exploratory -
49653/085   rosiglitazoneplacebo (add on insulin)Exploratory -
49653/095   rosiglitazoneplacebo (add on insulin)Exploratory -
saxagliptin
saxgliptin, renal study   saxagliptinplacebo (add on current treatment) -
CV181-057    NCTsaxagliptinplacebo (add on insulin) -
DeFronzo, 2009      NCTsaxagliptinplacebo (add on MET)negative
CV181-080    NCTsaxagliptinplacebo (add on MET) -
Jadzinsky, 2009      NCTsaxagliptinplacebo (add on MET) -
CV181-066    NCTsaxagliptinplacebo (add on MET) -
Hollander      NCTsaxagliptinplacebo (add on TZD) -
Rosenstock, 2008    NCTsaxagliptinplacebo (monotherapy) -
CV181-011      NCTsaxagliptinplacebo (monotherapy) -
CV181-038    NCTsaxagliptinplacebo (monotherapy) -
CV181-041    NCTsaxagliptinplacebo (monotherapy) -
saxagliptin vs sitagliptin   saxagliptinsitagliptin (add on MET) -
sitagliptin
Charbonnel, 2006      NCTsitagliptinplacebo (add on MET)negative
Nauck, 2007          NCTsitagliptinplacebo (add on MET)negative
Scott** (sit vs pbo on top met), 2007     sitagliptinplacebo (add on MET)negative
Rosenstock (sit on top pio vs pbo), 2006      NCTsitagliptinplacebo (on top PIO)suggesting
Hermansen, 2007     sitagliptinplacebo (on-top glimepiride+/- metformine)negative
taspoglutide
Nauck 10 once weekly vs PBO, 2009      NCTtaspoglutide 10mg once weeklyplaceboExploratory suggesting
Ratner (20mg once weekly), 2010      NCTtaspoglutideplacebo (add on MET)Exploratory suggesting
vildagliptin
Fonseca, 2007      NCTvildagliptinplacebo (add on insulin)Low risk of bias suggesting
Ahren, 2004     vildagliptinplacebo (add on MET)Low risk of bias negative
Bosi, 2007      NCTvildagliptinplacebo (add on MET)Low risk of bias negative
Goodman, 2009     vildagliptinplacebo (add on MET)Low risk of bias negative
Garber, 2007      NCTvildagliptinplacebo (on top pioglitazone)negative
Ferrannini, 2009      NCTvildagliptinSulfonylurea (add on to MET)Low risk of bias suggesting
Bolli, 2008        NCTvildagliptinpioglitazone (add on MET)Low risk of bias negative
Rosenstock** (vilda + pio vs pio), 2007      NCTvildagliptinplacebo (add on TZD)Low risk of bias negative